У нас вы можете посмотреть бесплатно Canaloplasty with, and without, Cataract surgery: 36-Month Outcomes with Dr. Mark Gallardo или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Welcome to episode 2 of the Canaloplasty Data Visualization Series. How does the IOP-lowering effect of canaloplasty differ when combined with cataract surgery, versus performed as a standalone procedure? In this episode, glaucoma specialist and researcher Dr. Mark Gallardo from El Paso dives into his published study with 36-month data comparing ab-interno canaloplasty as a standalone procedure versus its use combined with cataract surgery for treating open-angle glaucoma. Don’t miss this eye-opening breakdown of long-term outcomes and treatment strategies in glaucoma care—watch now! The iTrack™ Advance has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma. Indications for Use, USA: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The ab interno surgical technique is not a cleared indication for the iTrack™ Advance in the USA. The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma. Indications for Use, International: The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma. For more information in relation to approved labelling and indications for use, please visit https://itrack-advance.com/